Personalized sequencing and the future of medicine: discovery, diagnosis and defeat of disease.

The potential for personalized sequencing to individually optimize medical treatment in diseases such as cancer and for pharmacogenomic application is just beginning to be realized, and the utility of sequencing healthy individuals for managing health is also being explored. The data produced requires additional advancements in interpretation of variants of unknown significance to maximize clinical benefit. Nevertheless, personalized sequencing, only recently applied to clinical medicine, has already been broadly applied to the discovery and study of disease. It is poised to enable the earlier and more accurate diagnosis of disease risk and occurrence, guide prevention and individualized intervention as well as facilitate monitoring of healthy and treated patients, and play a role in the prevention and recurrence of future disease. This article documents the advancing capacity of personalized sequencing, reviews its impact on disease-oriented scientific discovery and anticipates its role in the future of medicine.

[1]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[2]  M. Zavoral,et al.  Mutation-based detection and monitoring of cell-free tumor DNA in peripheral blood of cancer patients. , 2013, Analytical biochemistry.

[3]  A. Roses,et al.  Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. , 2004, Pharmacogenomics.

[4]  P. Borst,et al.  High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs , 2008, Proceedings of the National Academy of Sciences.

[5]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[6]  Magalie S Leduc,et al.  Clinical whole-exome sequencing for the diagnosis of mendelian disorders. , 2013, The New England journal of medicine.

[7]  Kari Stefansson,et al.  A study based on whole-genome sequencing yields a rare variant at 8q24 associated with prostate cancer , 2012, Nature Genetics.

[8]  Howard L McLeod,et al.  Cancer Pharmacogenomics: Early Promise, But Concerted Effort Needed , 2013, Science.

[9]  P. Stankiewicz,et al.  Whole-genome sequencing in a patient with Charcot-Marie-Tooth neuropathy. , 2010, The New England journal of medicine.

[10]  Ole A. Andreassen,et al.  A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline , 2012, Nature.

[11]  E. Lander,et al.  Lessons from the Cancer Genome , 2013, Cell.

[12]  Madhuri Hegde,et al.  Assessment of clinical analytical sensitivity and specificity of next-generation sequencing for detection of simple and complex mutations , 2013, BMC Genetics.

[13]  Amy E. Hawkins,et al.  DNA sequencing of a cytogenetically normal acute myeloid leukemia genome , 2008, Nature.

[14]  Marc S. Williams,et al.  ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing , 2013, Genetics in Medicine.

[15]  P. Stenson,et al.  The Human Gene Mutation Database: building a comprehensive mutation repository for clinical and molecular genetics, diagnostic testing and personalized genomic medicine , 2013, Human Genetics.

[16]  W. Burke,et al.  Ancillary risk information and pharmacogenetic tests: social and policy implications , 2008, The Pharmacogenomics Journal.

[17]  Jonathan A. Bernstein,et al.  Clinical whole-exome sequencing: are we there yet? , 2014, Genetics in Medicine.

[18]  David R. Murdock,et al.  Whole-Genome Sequencing for Optimized Patient Management , 2011, Science Translational Medicine.

[19]  Peter Donnelly,et al.  Germline mutations in the proof-reading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas , 2012, Nature Genetics.

[20]  Daniel J. Freeman,et al.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  (Mis)treating the pharmacogenetic incidentalome , 2012, Nature Reviews Drug Discovery.

[22]  Peter Greenwald,et al.  Biomarkers for early detection and as surrogate endpoints in cancer prevention trials: issues and opportunities. , 2011, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[23]  R. Wilke,et al.  Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions. , 2012, Pharmacogenomics.

[24]  Muin J Khoury,et al.  Deploying whole genome sequencing in clinical practice and public health: Meeting the challenge one bin at a time , 2011, Genetics in Medicine.

[25]  Atul J Butte,et al.  Systematic evaluation of environmental factors: persistent pollutants and nutrients correlated with serum lipid levels , 2012, International journal of epidemiology.

[26]  Mark Gerstein,et al.  Personal phenotypes to go with personal genomes , 2009, Molecular systems biology.

[27]  Alexander A. Morgan,et al.  Clinical assessment incorporating a personal genome , 2010, The Lancet.

[28]  J. Shendure,et al.  Exome sequencing as a tool for Mendelian disease gene discovery , 2011, Nature Reviews Genetics.

[29]  Carlo C. Maley,et al.  Clonal evolution in cancer , 2012, Nature.

[30]  Peggy Hall,et al.  The NHGRI GWAS Catalog, a curated resource of SNP-trait associations , 2013, Nucleic Acids Res..

[31]  Jay Shendure,et al.  Noninvasive Whole-Genome Sequencing of a Human Fetus , 2012, Science Translational Medicine.

[32]  Kelly Schoch,et al.  Clinical application of exome sequencing in undiagnosed genetic conditions , 2012, Journal of Medical Genetics.

[33]  M. Eileen Dolan,et al.  Cancer pharmacogenomics: strategies and challenges , 2012, Nature Reviews Genetics.

[34]  Linghua Wang,et al.  From human genome to cancer genome: The first decade , 2013, Genome research.

[35]  M. Permutt,et al.  Missense mutations in the pancreatic islet beta cell inwardly rectifying K+ channel gene (KIR6.2/BIR ): a meta-analysis suggests a role in the polygenic basis of Type II diabetes mellitus in Caucasians , 1998, Diabetologia.

[36]  Mark Gerstein,et al.  Personal genome sequencing: current approaches and challenges. , 2010, Genes & development.

[37]  R. Collins,et al.  SLCO1B1 variants and statin-induced myopathy--a genomewide study. , 2008, The New England journal of medicine.

[38]  S. Mallal,et al.  HLA-B*5701 screening for hypersensitivity to abacavir. , 2008, The New England journal of medicine.

[39]  J J Swen,et al.  Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants , 2013, Clinical pharmacology and therapy.

[40]  Wei Zhang,et al.  PACdb: a database for cell-based pharmacogenomics. , 2010, Pharmacogenetics and genomics.

[41]  Atul J. Butte,et al.  An Environment-Wide Association Study (EWAS) on Type 2 Diabetes Mellitus , 2010, PloS one.

[42]  K. Sirotkin,et al.  The NCBI dbGaP database of genotypes and phenotypes , 2007, Nature Genetics.

[43]  S. Chanock,et al.  Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. , 2005, The New England journal of medicine.

[44]  P. Nowell.  The clonal evolution of tumor cell populations. , 1976, Science.

[45]  Thomas A. Peterson,et al.  Towards precision medicine: advances in computational approaches for the analysis of human variants. , 2013, Journal of molecular biology.

[46]  Eric E Schadt,et al.  Analytical validation of whole exome and whole genome sequencing for clinical applications , 2014, BMC Medical Genomics.

[47]  Eran Halperin,et al.  Identifying Personal Genomes by Surname Inference , 2013, Science.

[48]  H. Erlich,et al.  Evidence for association of the TCF7 locus with type I diabetes , 2009, Genes and Immunity.

[49]  F. Collins,et al.  Potential etiologic and functional implications of genome-wide association loci for human diseases and traits , 2009, Proceedings of the National Academy of Sciences.

[50]  Joshua C. Denny,et al.  Mapping the incidentalome: estimating incidental findings generated through clinical pharmacogenomics testing , 2012, Genetics in Medicine.

[51]  Markus Perola,et al.  Lessons from studying monogenic disease for common disease. , 2006, Human molecular genetics.

[52]  S. Weissman,et al.  Genetic Testing by Cancer Site: Ovary , 2012, Cancer journal.

[53]  I Tomlinson,et al.  Technical and implementation issues in using next-generation sequencing of cancers in clinical practice , 2013, British Journal of Cancer.

[54]  A. Chittenden,et al.  Genetic testing by cancer site: breast. , 2012, Cancer journal.

[55]  C. Moore,et al.  Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir , 2002, The Lancet.

[56]  Eric Vilain,et al.  Assessing the necessity of confirmatory testing for exome sequencing results in a clinical molecular diagnostic laboratory , 2014, Genetics in Medicine.

[57]  Á. Carracedo,et al.  New genes emerging for colorectal cancer predisposition. , 2014, World journal of gastroenterology.

[58]  Euan A Ashley,et al.  Clinical interpretation and implications of whole-genome sequencing. , 2014, JAMA.

[59]  K. Jasperson.  Genetic Testing by Cancer Site: Colon (Polyposis Syndromes) , 2012, Cancer journal.

[60]  Alan Ashworth,et al.  Mechanisms of resistance to therapies targeting BRCA-mutant cancers , 2013, Nature Medicine.

[61]  A. Ashworth,et al.  Genetic Interactions in Cancer Progression and Treatment , 2011, Cell.

[62]  A. Hofman,et al.  Variant of TREM2 associated with the risk of Alzheimer's disease. , 2013, The New England journal of medicine.

[63]  Hugo Y. K. Lam,et al.  Personal Omics Profiling Reveals Dynamic Molecular and Medical Phenotypes , 2012, Cell.

[64]  C. Leen.  HLA B∗5701 status, disease progression, and response to antiretroviral therapy , 2013, AIDS.

[65]  U. Ladabaum,et al.  Comparative Effectiveness and Cost-Effectiveness of Screening Colonoscopy vs. Sigmoidoscopy and Alternative Strategies , 2013, The American Journal of Gastroenterology.

[66]  H. Ohtsuki,et al.  Accumulation of driver and passenger mutations during tumor progression , 2009, Proceedings of the National Academy of Sciences.

[67]  R. Mathijssen,et al.  Individualization of Tamoxifen Treatment for Breast Carcinoma , 2012, Clinical pharmacology and therapeutics.

[68]  Yuchen Jiao,et al.  ATM mutations in patients with hereditary pancreatic cancer. , 2012, Cancer discovery.

[69]  Daniel A. Haber,et al.  Epidermal growth factor receptor mutations in lung cancer , 2007, Nature Reviews Cancer.

[70]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[71]  B. Balkau,et al.  The Common P446L Polymorphism in GCKR Inversely Modulates Fasting Glucose and Triglyceride Levels and Reduces Type 2 Diabetes Risk in the DESIR Prospective General French Population , 2008, Diabetes.

[72]  Darragh G. McArt,et al.  Validation of Next Generation Sequencing Technologies in Comparison to Current Diagnostic Gold Standards for BRAF, EGFR and KRAS Mutational Analysis , 2013, PloS one.

[73]  Andrew M. K. Brown,et al.  Variable Clonal Repopulation Dynamics Influence Chemotherapy Response in Colorectal Cancer , 2013, Science.

[74]  A. Ashworth,et al.  Therapeutic potential of PARP inhibitors for metastatic breast cancer , 2011, Expert review of anticancer therapy.

[75]  Yan Peng,et al.  Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy. , 2013, Pharmacogenomics.

[76]  Rong Chen,et al.  Data-driven integration of epidemiological and toxicological data to select candidate interacting genes and environmental factors in association with disease , 2012, Bioinform..

[77]  W. Miller,et al.  Sequencing and analysis of a South Asian-Indian personal genome , 2012, BMC Genomics.

[78]  David P Bick,et al.  Making a definitive diagnosis: Successful clinical application of whole exome sequencing in a child with intractable inflammatory bowel disease , 2011, Genetics in Medicine.

[79]  M. Gabree,et al.  Genetic Testing by Cancer Site: Skin , 2012, Cancer journal.

[80]  L. Senter.  Genetic testing by cancer site: colon (nonpolyposis syndromes). , 2012, Cancer journal.

[81]  R. Altman,et al.  Databases in the area of pharmacogenetics , 2011, Human mutation.

[82]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[83]  P. Shannon,et al.  Exome sequencing identifies the cause of a Mendelian disorder , 2009, Nature Genetics.

[84]  Laura E. MacConaill,et al.  Existing and emerging technologies for tumor genomic profiling. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  N. Norton,et al.  Next-generation sequencing to identify genetic causes of cardiomyopathies , 2012, Current opinion in cardiology.

[86]  J. Ford,et al.  Genetic Testing by Cancer Site: Stomach , 2012, Cancer journal.

[87]  Sundhiya Mandalia,et al.  Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience , 2007, AIDS.

[88]  F. Collins,et al.  A vision for the future of genomics research , 2003, Nature.